Cellular-molecular mechanisms of liver fibrosis: the role of micro-RNA-122 in chronic viral hepatitis
https://doi.org/10.31146/1682-8658-ecg-180-8-50-53
Abstract
This article provides all the information to date about the role of micro-RNA in the development of liver fibrosis and the degree of inflammation in chronic viral liver diseases. To write the article, information was searched using the databases Scopus, Web of Science, MedLine, PubMed, and Google Scholar. Circulating microRNA-122 were evaluated as potential non-invasive biomarkers of liver fibrosis activation and prognosis in patients with chronic viral hepatitis.
Micro-RNAs are potential markers for the diagnosis and monitoring of liver tissue, including the processes of fibrosis and carcinogenesis. The therapeutic effectiveness and advantages of using UDCA on microRNA-122 expression are considered.
About the Authors
D. A. Parpiboeva
Tashkent medical Academy
Uzbekistan
Uzbekistan
Dinora A. Parpiboeva - Cand. of Med. Sci., associate Professor of the Department of propedeutics of internal diseases № 2.
Tashkent
F. N. Shukurova
Tashkent medical Academy
Uzbekistan
Uzbekistan
Fazilat N. Shukurova - assistant of the Department of propaedeutics of internal diseases № 2.
Tashkent
M. Sh. Karimov
Tashkent medical Academy
Uzbekistan
Uzbekistan
Marif Sh. Karimov - doctor of medical Sciences, Professor, head of the Department of propaedeutics of internal diseases № 2.
Tashkent
References
1. Olson J. C. Acute-on-chronic and decompensated chronic liver failure: definitions, epidemiology and prognostication. Crit Care Clin. 2016, Vol. 32, no. 3, pp. 301–309.
2. Pares A., Planas R., Torres M. et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, doubleblind, randomized and multicenter trial. J Hepatol. 1998, Vol. 28, no. 4, pp. 615–621.
3. Sayiner M., Koenig A., Henry L., Younossi Z. M. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016, Vol. 20, no. 2, pp. 205–214.
4. Rino Y, Yukawa N, Yamamoto N. Does herbal medicine reduce the risk of hepatocellular carcinoma?. World J Gastroenterol. 2015, Vol. 21, no. 37, pp. 10598–10603.
5. Tsubota A., Kumada H. Th erapeutic strategies for hepatitis C. Nihon Rinsho. 2004, Vol. 62, Suppl. 7 (Pt 1), pp. 441–447.
6. Trinchet J. C., Coste T., Lévy V. G. et al. Treatment of alcoholic hepatitis with silymarin. A double-blind com-parative study in 116 patients. Gastroenterol Clin Biol. 1989, Vol. 13, no. 2, pp. 120–124.
7. Otsuka M, Kishikawa T, Yoshikawa T, et al. MicroRNAs and liver disease. J Hum Genet. 2017, Jan, 62(1), pp.75–80. doi: 10.1038/jhg.2016.53.
8. Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic me-tastasis of hepatocellular carcinoma. Hepatology. 2009 May;49(5):1571–82. doi: 10.1002/hep.22806.
9. Castro RE, Ferreira DM, Zhang X, et al. Identifi cation of microRNAs during rat liver regeneration aft er partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gas-trointest Liver Physiol. 2010 Oct; 299(4): G887–97. doi: 10.1152/ajpgi.00216.2010.
10. Sato T., Liu X., Nelson A., Nakanishi M., Kanaji N., Wang X., Kim M., Li Y., Sun J., Michalski J., Patil A., Basma H., Holz O., Magnussen H., Rennard S. I. Reduced miR-146a increases prostaglandin E2 in chronic ob-structive pulmonary disease fi broblasts. Am. J. Respir.
11. Crit. Care Med., 2010, vol. 182, no. 8, pp. 1020–1029. doi: 10.1164/rccm.201001–0055OC
12. Sakamoto T, Morishita A, Nomura T, et al. Identifi cation of microRNA profi les associated with refractory primary biliary cirrhosis. Mol Med Rep. 2016 0ct;14(4):3350–6. doi: 10.3892/mmr.2016.5606.
Review
For citations:
Parpiboeva D.A., Shukurova F.N., Karimov M.Sh. Cellular-molecular mechanisms of liver fibrosis: the role of micro-RNA-122 in chronic viral hepatitis. Experimental and Clinical Gastroenterology. 2020;(8):50-53. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-180-8-50-53
Views:
293
Email this article 